Pharmalive?s Annual ?New Drug Review And Outlook? Special Report Analyzes Market Impact Of Recently Approved Medicines And Potential Blockbusters In Clinical Development
NEWTOWN, Pa., March 31, 2010 –– Canon Data Products Group and PharmaLive.com announce the release of their annual Special Report, New Drug Review and Outlook. This report provides professionals working in or serving the pharmaceutical and biotechnology industries with analysis of recently approved drugs and compounds in development that have potential to generate blockbuster sales. Insight is provided into each drug’s expected market impact as well as opportunities and challenges for companies operating within this sector.
During 2009, FDA cleared 92 new medicines for marketing, representing the most new drug approvals since 2006. The list of new medicines includes 25 new molecular entities and biologics, which is the highest amount approved in one year since 2004. Recent changes in FDA leadership and policies have been credited for the improvement of on-time review performance.
“The Food and Drug Administration has generated solid progress in terms of the overall drug-approval process during the past couple of years,” says Andrew Humphreys, editor in chief of Canon Data Products Group. “During 2010, U.S. regulators will give the green light to promising first-in-class medicines, such as AstraZeneca’s Brilinta for reducing major adverse cardiac events in patients with acute coronary syndrome.”
New Drug Review and Outlook presents analysis of the following:
• Potential Blockbusters – details the expected
market impact of some of the most-anticipated products expected to
emerge from the late-stage industry pipeline.
• Products Awaiting FDA Clearance – lists the new drugs awaiting first-time FDA approval.
• FDA’s New Medicines of 2009 – overview of the 92 new prescription medicines that were approved via a new drug application (NDA) or biologic license application (BLA) in the United States during 2009.
• U.S. Approvals Over Time – alphabetical listing of 1,600 products that have been approved by FDA via an NDA or BLA since 1990.
This annual Special Report is available at www.PharmaLive.com/specialreports.
For more information, contact Sandra Baker at 215-944-9836 or Sandra.Baker@cancom.com.
About Canon Data Products Group
Canon Data Products Group, a division of Canon Communications LLC, publishes PharmaLive and Appliance Special Reports, which provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries; maintains eKnowledgeBase, a comprehensive market intelligence tool serving the pharmaceutical, biotechnology, and medical device sectors; and manages company-wide Site Licenses for PharmaLive.com, Med Ad News, and R&D Directions.
Posted: March 2010